Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global neurothrombectomy devices market was valued at US$ 560 million in 2021 and is expected to register a revenue CAGR of 9.30% to reach US$ 1246.7 million by 2030.

Neurothrombectomy Devices Market Fundamentals

Ischemic stroke occurs when blood clots block the blood flow toward the brain, and brain cells start to die due to the lack of oxygen, resulting in a stroke. Neurothrombectomy devices are intended for blood clot removal and retrieving clots to treat ischemic stroke. Neurothrombectomy devices are classified as aspiration and clot retrievers.

[458035]

Neurothrombectomy Devices Market Dynamics

The global neurothrombectomy devices market is driven by increasing prevalence of ischemic stroke, high blood pressure, high cholesterol, and cardiovascular diseases. Additionally, technological advancements and introduction of novel products contribute to the neurothrombectomy market revenue growth. Moreover, favorable reimbursement policies and increasing diagnosis testing contribute to the revenue growth of the market.

However, high costs of neurothrombectomy devices and need for skilled professionals are likely to restrain the revenue growth of the neurothrombectomy market. 

Neurothrombectomy Devices Market Ecosystem

The global neurothrombectomy devices market has been analyzed from three perspectives: device type, end-user, and region. 

Neurothrombectomy Devices Market by Device Type

[245466]

Based on the device type, the global neurothrombectomy devices market is segmented into aspiration devices and clot retrievers.

The clot retrievers segment accounts for the largest revenue share of the global neurothrombectomy market owing to increasing adoption of clot retriever devices, rising investment in R&D activities, and product launches. Additionally, growing prevalence of cardiovascular diseases and thrombophilia contributes to the revenue growth of this segment.

Neurothrombectomy Devices Market by End-user

Based on the end-user, the global neurothrombectomy devices market is segmented into hospitals, specialty clinics, ambulatory centers, and others.

The hospitals segment leads the global neurothrombectomy devices market in terms of revenue share, owing to rise in the requirement of urgent medical attention, adoption of novel technologies, and increase in patient footfall in hospitals for diagnosis and treatment. Moreover, favorable reimbursement policies, growing prevalence of chronic diseases, such as cardiovascular diseases, and strategies adopted by prominent players and hospitals contribute to the segment’s revenue growth.

Neurothrombectomy Devices Market by Region

Based on the region, the global neurothrombectomy devices market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America dominates the global neurothrombectomy devices market in terms of revenue share. This is attributed to increasing prevalence of chronic diseases, technological advancements, well-developed infrastructure, and top-notch health services available in the region. Additionally, rising healthcare expenditure, high adoption rate of novel treatments, and favorable reimbursement policies are contributing to the revenue growth of the market in North America.

Neurothrombectomy Devices Market Competitive Landscape

The prominent players operating in the global neurothrombectomy devices market are:

• Acandis GmbH
• Boston Scientific Corporation
• Medtronic Plc
• MicroVention Inc.
• Penumbra, Inc.
• Phenox GmbH
• Stryker
• Vesalio

Neurothrombectomy Devices Market Strategic Developments

• In April 2022, Medtronic launched a registry system for collecting real-world data associated with using revascularization devices for ischemic stroke patients. The Prospective Registry for Assessment of Acute Ischemic Stroke Patients Treated with Neurothrombectomy Devices in India (PRAAN) is an industry-first effort to establish a post-market registration system to evaluate treatment advantages associated with the usage of Medtronic market-released revascularization devices in patients suffering from acute ischemic stroke.
• In February 2022, Imperative Care launched the first and only Zoom POD stroke treatment filter to capture clots in the sterile field. Zoom POD stroke solution offers quick and successful clot retrieval during mechanical thrombectomy procedures as a treatment for ischemic stroke.
• In August 2021, Holland Hospital and Metro Health announced a strategic partnership to provide stroke-focused novel medical procedure neurothrombectomy. A multidisciplinary team of Holland Hospital and Metro Health experts are trained to perform these procedures in Holland Hospital's Cath lab special procedures room.

Frequently Asked Questions About This Report